Dermatology update: The dawn of targeted treatment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25973879.
- Also identified by DOI 10.3949/ccjm.82gr.15002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
During the past several years, targeted therapies have significantly improved outcomes in advanced basal cell carcinoma, psoriasis, and metastatic melanoma. This article reviews how advances in our understanding of the molecular pathogenesis of these diseases led to the development of targeted therapies and how these therapies are improving outcomes. Research is ongoing to address continuing challenges of drug resistance, adverse effects, and how best to use the new medications.
Medical subject headings
- Antineoplastic Agents
- Brain Neoplasms
- Basal Cell Carcinoma
- Dermatologic Agents
- Melanoma
- Psoriasis
- Skin Neoplasms